Century Therapeutics targets CNTY-813 IND filing in Q4 2026, sees initial trial data in 2H 2027

• Century Therapeutics outlined new nonclinical results for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, presented at EASD 2026.
• Animal studies showed durable blood-sugar control that persisted until graft removal, supporting pharmacological activity and functional insulin response.
• Manufacturing updates indicated consistent clinical-scale production, supporting readiness to supply an initial human study.
• The company kept its timeline for an IND filing in Q4 2026, with initial clinical data expected in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020805PRIMZONEFULLFEED9838151) on October 02, 2026, and is solely responsible for the information contained therein.